Meda

Meda

Meda AB is an international specialty pharmaceutical company. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2015
R&D budget23.0m

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-

$7.2b

Acquisition
Total Funding-

Recent News about Meda

Edit
More about Medainfo icon
Edit

Viatris, formerly known as Mylan, is a global healthcare company dedicated to empowering people to live healthier lives at every stage. The company focuses on increasing access to high-quality medicines for patients worldwide, ensuring they receive the treatments they need when and where they need them. Viatris operates in the pharmaceutical industry, serving a diverse range of clients including healthcare providers, pharmacies, and patients. The company generates revenue through the development, manufacturing, and distribution of a broad portfolio of generic and branded medications. Viatris leverages its extensive global infrastructure and expertise to deliver cost-effective healthcare solutions, aiming to improve health outcomes and reduce healthcare costs. The company's business model is centered around innovation, quality, and accessibility, striving to meet the evolving needs of the global healthcare market.

Keywords: healthcare, pharmaceuticals, generic medicines, branded medications, global access, patient care, cost-effective, innovation, quality, infrastructure.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Meda

Edit
ConferPlace
ACQUISITION by Meda Oct 2014
Acton Pharmaceuticals
ACQUISITION by Meda Aug 2013
Rottapharm
ACQUISITION by Meda Jul 2014
Healthcare Brands International
ACQUISITION by Meda Jan 2011